Hery F, Hamon M
Laboratoire de Neuroendocrinologie Expérimentale, INSERM U 297, UER de Médecine Nord, Marseille.
Encephale. 1993 Sep-Oct;19(5):525-32.
To date, there is no doubt that dopamine plays a key role in the behavioural disorders associated with schizophrenia. However, dopamine is not the only neurotransmitter involved in this syndrome, as it interacts with many neuronal systems in brain. Of special interest is the interaction between dopaminergic and serotoninergic systems with evidence from pharmacological data in animals that each of these systems may exert an inhibitory influence on the other. Furthermore, the psychotomimetic effects of drugs affecting serotoninergic neurotransmission such as LSD, psilocybin, N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine also contributed to draw attention onto a possible involvement of serotoninergic systems in at least some of the disorders typical of schizophrenia. This idea received strong support from recent studies on the multiple receptors for serotonin in the central nervous system. These studies not only demonstrate the existence of several classes of serotonin receptors called 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, 5-HT2, 5-HT3 and 5-HT4, but led also to the development of novel agonists and antagonists for the stimulation or blockade of each of them. Pharmacological investigations with these ligands revealed that serotonin is probably involved in the behavioural disorders associated with schizophrenia through its binding to three distinct classes of receptors: 5-HT1A, 5-HT2 (or the closely related class 5-HT1C) and 5-HT3.(ABSTRACT TRUNCATED AT 250 WORDS)
迄今为止,多巴胺在与精神分裂症相关的行为障碍中发挥关键作用这一点毋庸置疑。然而,多巴胺并非参与该综合征的唯一神经递质,因为它与大脑中的许多神经元系统相互作用。特别值得关注的是多巴胺能系统与5-羟色胺能系统之间的相互作用,动物药理学数据表明,这两个系统可能相互施加抑制性影响。此外,影响5-羟色胺能神经传递的药物(如麦角酸二乙胺、裸盖菇素、N,N-二甲基色胺和5-甲氧基-N,N-二甲基色胺)的拟精神病效应也促使人们关注5-羟色胺能系统至少在某些典型精神分裂症疾病中可能发挥的作用。这一观点得到了近期关于中枢神经系统中5-羟色胺多种受体研究的有力支持。这些研究不仅证明了存在几类5-羟色胺受体,分别称为5-HT1A、5-HT1B、5-HT1C、5-HT1D、5-HT2、5-HT3和5-HT4,还促使开发出了用于刺激或阻断每种受体的新型激动剂和拮抗剂。对这些配体的药理学研究表明,5-羟色胺可能通过与三类不同的受体结合而参与与精神分裂症相关的行为障碍:5-HT1A、5-HT2(或密切相关的5-HT1C类)和5-HT3。(摘要截选至250字)